TCTC for Metabolic Immune Disease
Globally, around 463 million adults are affected by diabetes, and approximately 10% of the Taiwanese population is impacted.
In recent years, innovative sodium-glucose co-transporter-2 (SGLT2) inhibitors have not only been proven to lower blood sugar but also shown to delay the progression of kidney disease and provide cardiovascular protection.
This is a global initiative led by the University of Oxford, with Taipei Medical University serving as the regional coordinating center Regional Coordinating Centre, RCC) for the Asian region.
Renal Disease category
Reduces the risk of kidney disease in both diabetic and non-diabetic patients.
This study will investigate the effectiveness and safety of an aldosterone synthase inhibitor (ASI) added to standard treatment (including SGLT2 inhibitors and a clinically appropriate dose of a renin-angiotensin system blocker) for both diabetic and non-diabetic high-risk patients.
Global Cooperation:
Following the establishment of the Taiwan Metabolic and Immunologic Disease Clinical Trial Consortium at Taipei Medical University, this international research project will serve as the consortium's inaugural execution plan. The goal is to introduce world-class advanced clinical trial concepts domestically, foster collaboration with other domestic consortia, strengthen the country's clinical trial capabilities, cultivate a resilient and sustainable partnership network, and nurture a pool of clinical trial talent. Ultimately, through excellent enrollment efficiency and trial quality, it aims to attract more global research collaborations, aligning Taiwan's medical capabilities with international standards.
Economic benefits:
(1).Globally, around 463 million adults are affected by diabetes, and approximately 10% of the Taiwanese population is impacted. This disease is associated with high rates of cardiovascular and renal complications, resulting in elevated mortality rates and very high medical expenses.
(2).BI 690517(Boehringer Ingelheim) in combination with empagliflozin), phase Ⅲ clinical trial
(3).This study will investigate the effectiveness and safety of an aldosterone synthase inhibitor (ASI) added to standard treatment (including SGLT2 inhibitors and a clinically appropriate dose of a renin-angiotensin system blocker) for both diabetic and non-diabetic high-risk patients. This disease is associated with high cardiovascular and renal comorbidities, resulting in a high risk of mortality and a very high medical economic burden.
Taipei Municipal Wanfang Hospital
National Taiwan University Hospital
Taipei Veterans General Hospital
Tri-Service General Hospital
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
National Taiwan University Hsin-Chu Branch
Chang Gung Memorial Hospital, Linkou
Chang Gung Memorial Hospital, Keelung
Taichung Veterans General Hospital
China Medical University Hospital
Chung Shan Medical University Hospital
Kaohsiung Medical University Chung-Ho Memorial Hospital
Chang Gung Memorial Hospital, Chiayi
Far Eastern Memorial Hospital
Saint Mary's Hospital Luodong
Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Taipei Medical University Shuang-Ho Hospital, Ministry of Health and Welfare
Taipei Medical University Hospital
Contact Information
c-IRB